Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: Heparin's effect on binding

Acta Medica Okayama

Volumn 63, Issue 4, 2009, Pages 203-211

  Liua, Rui ^a,b   Mori, Shuji ^c   Wake, Hidenori ^b   Zhang, Jiyong ^b   Liu, Keyue ^b   Izushi, Yasuhisa ^b   Takahashi, Hideo K ^b   Peng, Bo ^a   Nishibori, Masahiro ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b OKAYAMA UNIVERSITY   (Japan)

^c SHUJITSU UNIVERSITY   (Japan)

Author keywords

Heparin; HMGB1; Inflammation; RAGE; S100A12

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIINFLAMMATORY AGENT; CALCIUM; HEPARIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN RECEPTOR; PROTEIN S 100; S100A12 PROTEIN, HUMAN; ZINC;

AFFINITY CHROMATOGRAPHY; ARTICLE; HUMAN; METABOLISM;

ANTI-INFLAMMATORY AGENTS; CALCIUM; CHROMATOGRAPHY, AFFINITY; HEPARIN; HMGB1 PROTEIN; HUMANS; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; ZINC;

EID: 70349329428     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Chavakis T, Bierhaus A and Nawroth PP: RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect (2004) 6: 1219-1225.
2. Bierhaus A, Stern DM and Nawroth PP: RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs (2006) 7: 985-991
3. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W and Clauss M: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 267: 14987-14997.
4. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW and Chazin WJ: The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry (2007) 46: 6957-6970.
5. Yamagishi S, Matsui T and Nakamura K: Kinetics, role and thera peutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets (2007) 8: 1138-1143.
6. Yamagishi S, Nakamura K and Matsui T: Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol (2006) 3: 83-88.
7. Unoshima M: Therapeutic effect of anti-HMGB1 antibody and anti-RAGE anibody on SIRS/sepsis. Nippon Rinsho (2004) 62: 2323-2329 in Japanese.
8. Mruthinti S, Schade RF, Harrell DU, Gulati NK, Swamy-Mruthinti S, Lee GP and Buccafusco JJ: Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes. Curr Alzheimer Res (2006) 3: 229-235.
9. Carroll L, Hannawi S, Marwick T and Thomas R: Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. Wien Med Wochenschr (2006) 156: 42-52.
10. Sisková A and Wilhelm J: Role of nonenzymatic glycation and oxidative stress on the development of complicated diabetic cata racts. Cesk Fysiol (2000) 49: 16-21 in Czech.
11. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin pro tein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418: 191-195.
12. Abraham E, Arcaroli J, Carmody A, Wang H and Tracey KJ: HMG-1 as a mediator of acute lung inflammation. J Immunol (2000) 165: 2950-2954.
13. Zimmer DB, Cornwall EH, Landar A and Song W: The S100 pro tein family: history, function, and expression. Brain Res Bull (1995)37: 417-429.
14. Vogl T, Pröpper C, Hartmann M, Strey A, Strupat K, van den Bos C, Sorg C and Roth J: S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem (1999) 274: 25291-25296.
15. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D and Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999)97: 889-901.
16. Alban S: Pharmacology of heparins and direct anticoagulants. Hamostaseologie (2008) 28: 400-420.
17. Tefferi A, Owen BA, Nichols WL, Witzig TE and Owen WG: Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma. Blood (1989) 74: 252-254.
18. Tyrell DJ, Kilfeather S and Page CP: Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci (1995) 16: 198-204.
19. Gaffney A and Gaffney P: Rheumatoid arthritis and heparin. Br J Rheumatol (1996) 35: 808-809.
20. Prajapati DN, Newcomer JR, Emmons J, Abu-Hajir M and Binion DG: Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis (2002) 8: 192-195.
21. Myint KM, Yamamoto Y, Doi T, Kato I, HarashimaA, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H and Yamamoto H: RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes (2006) 55: 2510-2522.
22. Rauvala H and Pihlaskari R: Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem (1987) 262: 16625-16635.
23. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J and Rauvala H: 30-kDa heparin binding protein of brain (amphoterin) involved in neurite outgrowth. J Biol Chem (1991) 266: 16722-16729.
24. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N and Rauvala H: Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol (2007) 81: 49-58.
25. Moroz OV, Antson AA, Dodson GG, Wilson KS, Skibshoj I, Lukanidin EM, Bronstein IB: Crystallization and preliminary X-ray diffraction analysis of human calcium-binding protein S100A12. Acta Crystallogr D Biol Crystallogr (2000) 56: 189-191.
26. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 97: 889-901.
27. Hoppensteadt D, Walenga JM, Fareed J and Bick RL: Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am (2003) 17: 313-341.
28. Spyropoulos AC: Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight hepa rin? Clin Cornerstone (2005) 7: 39-48
29. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C and Ubrich N: Oral bioavailability of a low molecular weight hepa rin using a polymeric delivery system. J Control Release (2006) 113: 38-42.
30. Scheuch G, Brand P, Meyer T, Herpich C, Müllinger B, Brom J, Weidinger G, Kohlhäufl M, Häussinger K, Spannagl M, Schramm W and Siekmeier R: Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. J Physiol Pharmacol (2007) 58 Suppl 5: 603-614.
31. Tyrrell DJ, Horne AP, Holme KR, Preuss JM and Page CP: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol (1999) 46: 151-208.
32. Wang L, Brown JR, Varki A and Esko JD: Heparin's anti-inflam matory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest (2002) 110: 127-136.
33. Fareed J, Hoppensteadt DA and Bick RL: An update on heparins at the beginning of the new millennium. Semin Thromb Hemost (2000)26: 5-21.
34. Esmon CT: Coagulation inhibitors in inflammation. Biochem Soc Trans (2005) 33: 401-405.
35. Schouten M, WiersingaWJ, Levi M and van der Poll T: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol (2008) 83: 536-545.
36. Jaimes F and de la Rosa G: Anticoagulation and sepsis: the opportunity for a new use of heparin? Biomedica (2006) 26: 150-160
37. Okajima K: Regulation of inflammatory responses by natural anti coagulants. Immunol Rev (2001) 184: 258-274.
38. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K and Schmidt AM: Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med (2007) 7: 743-751.
39. Yan SF, Ramasamy R, Naka Y and Schmidt AM: Glycation, inflammation, and RAGE: a scaffold for the macrovascular compli cations of diabetes and beyond. Circ Res (2003) 93: 1159-1169.
40. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP and Chavakis T: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 26: 1129-1139.